3 terminated. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 3 |
| Phase 2 | 2 | Terminated 2 |
Follow CureTech Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma lenalidomide, pidilizumab, pharmacological study - Multiple Myeloma | Phase 1 | Terminated | Ohio State University Comprehensive Cancer Center | 20 | 2014-03-03 | 2023-01-27 |
| Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma CT-011 - Primary Hepatocellular Carcinoma | Phase 1 / Phase 2 | Terminated | CureTech Ltd | 2 | 2009-10-01 | 2012-10-23 |
| Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection CT-011 - Chronic Hepatitis C | Phase 1 / Phase 2 | Terminated | CureTech Ltd | 13 | 2009-09-01 | 2014-08-29 |
Carcinoma, Hepatocellular (1) · Hepatitis C, Chronic (1) · Liver Diseases (1) · Multiple Myeloma (1)
pidilizumab (3) · Lenalidomide (1)
Israel (2) · United States (1)
Yaron Ilan, MD (2) · Yvonne Efebera (1)